Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk

With the growing burden of metabolic disease, cardiovascular disease, and diabetes mellitus, there is an implication for new pharmacological intervention. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a class of drugs that work on SGLT2 receptors in the kidneys to decrease glucose reabsorpt...

Descripción completa

Detalles Bibliográficos
Autores principales: Jasleen, Bains, Vishal, Gupta K, Sameera, Malepati, Fahad, Molla, Brendan, O'Brien, Deion, Santander, Pemminati, Sudhakar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937770/
https://www.ncbi.nlm.nih.gov/pubmed/36819350
http://dx.doi.org/10.7759/cureus.33939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937770/
https://www.ncbi.nlm.nih.gov/pubmed/36819350
http://dx.doi.org/10.7759/cureus.33939

Ejemplares similares